CYP19A1 and breast cancer: Patients with postmenopausal nonmetastatic estrogen receptor–positive (ER+) breast cancer (BC) in maintenance therapy with an aromatase inhibitor (AI) deal with numerous long-term cancer- and treatment-related side effects (eg, affected bone health).